Executives
-
Altshuler DavidEVP, Chief Scientific Officer -
Kewalramani ReshmaCEO & President
-
Biller JonathanEVP and Chief Legal Officer
-
Leiden Jeffrey MExecutive Chairman
-
Bozic CarmenEVP and CMO
-
Atkinson Edward Morrow IiiEVP, Chief Technical Ops. Off.
-
Sachdev AmitEVP Chief Patient & Ext Af Off
-
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
-
Ambrose KristenSVP & Chief Accounting Officer
?
Leiden Jeffrey M
Executive Chairman
Vertex Pharmaceuticals Incorporated
US, Boston [HQ]
CIK
1242825
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
12,887
Price per Share :
$419.92
Equivalence :
$5,411,509.04
Transaction History
-
A12,887 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/06/24
-
Footnotes
-
-
Footnotes:#1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.#2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/10/2024.#3 Restricted stock unit award that fully vested upon grant.
-
A33,339 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/06/24
-
Footnotes
-
-
Footnotes:#1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.#2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/10/2024.#3 Restricted stock unit award that fully vested upon grant.
-
A41,046 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/07/24
-
Footnotes
-
-
Footnotes:#1 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.#2 Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/10/2024.#3 Restricted stock unit award that fully vested upon grant.
-
S28,291 Shares After TransactionValue : $11,860,153.02Sold $842,212.98Transaction Date : 02/12/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023.#2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.#3 Open market sales reported on this line occurred at a weighted average price of $419.22 (range $419.00 to $419.71).#4 Open market sales reported on this line occurred at a weighted average price of $420.39 (range $420.21 to $420.94).
-
S27,644 Shares After TransactionValue : $11,621,261.16Sold $271,992.33Transaction Date : 02/12/24
-
Footnotes
-
-
Footnotes:#1 Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023.#2 Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.#3 Open market sales reported on this line occurred at a weighted average price of $419.22 (range $419.00 to $419.71).#4 Open market sales reported on this line occurred at a weighted average price of $420.39 (range $420.21 to $420.94).